These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 15919455)

  • 1. The pathologic impact of tacrolimus on protocol biopsy in renal transplant patients with basiliximab-based immunosuppression.
    Sakai K; Miyagi Y; Hasegawa T; Itabashi Y; Muramatsu M; Sugiyama K; Kawamura T; Arai K; Aikawa A; Ohara T; Mizuiri S; Hasegawa A
    Transplant Proc; 2005 May; 37(4):1757-9. PubMed ID: 15919455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
    Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
    Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
    Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient.
    Montini G; Murer L; Ghio L; Pietrobon B; Ginevri F; Ferraresso M; Cardillo M; Scalamogna M; Perfumo F; Edefonti A; Zanon GF; Zacchello G
    Transpl Int; 2005 Jan; 18(1):36-42. PubMed ID: 15612981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protocol biopsies in pediatric renal transplant recipients on cyclosporine versus tacrolimus-based immunosuppression.
    Aoun B; Decramer S; Vitkevic R; Wannous H; Bandin F; Azema C; Callard P; Brocheriou I; Ulinski T
    Pediatr Nephrol; 2013 Mar; 28(3):493-8. PubMed ID: 23111894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basiliximab and mycophenolate mofetil in combination with low-dose cyclosporine and methylprednisolone effectively prevent acute rejection in kidney transplant recipients.
    Kovac D; Kotnik V; Kandus A
    Transplant Proc; 2005 Dec; 37(10):4230-4. PubMed ID: 16387086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of basiliximab on renal allograft rejection within 1 year after transplantation.
    Lee BM; Oh CK; Jin SH; Kim JH; Kim SJ; Kim H; Shin GT
    Transplant Proc; 2006 Sep; 38(7):2025-8. PubMed ID: 16979988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolate mofetil in pediatric renal transplantation: non-induction vs. induction with basiliximab.
    Ojogho O; Sahney S; Cutler D; Baron PW; Abdelhalim FM; James S; Zuppan C; Franco E; Concepcion W
    Pediatr Transplant; 2005 Feb; 9(1):80-3. PubMed ID: 15667617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quadruple immunosuppression with basiliximab, tacrolimus, mycophenolate mofetil and prednisone is safe and effective for renal transplantation.
    Miura M; Harada H; Fukuzawa N; Iwami D; Taniguchi A; Seki T; Togashi M; Ogawa Y; Satoh H; Hirano T
    Clin Transplant; 2005; 19 Suppl 14():54-8. PubMed ID: 15955170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of kidney transplantation in patients receiving MMF- or MMF and basiliximab-containing immunosuppression.
    Tojimbara T; Nakajima I; Sato S; Nakamura M; Kawase T; Kai K; Tsuda S; Kudo S; Fuchinoue S; Teraoka S
    Transplant Proc; 2004 Sep; 36(7):2087-9. PubMed ID: 15518755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of clinical outcome in kidney transplantation between early steroid withdrawal protocol using basiliximab, calcineurin inhibitor, and mycophenolate mofetil and triple regimen consisting of calcineurin inhibitor, mycophenolate mofetil, and steroid.
    Teraoka S; Sato S; Sekijima M; Iwado K; Urashima Y; Kudo S; Kai K; Koyama I; Tojinbara T; Nakajima I; Fuchinoue S
    Transplant Proc; 2005 Mar; 37(2):791-4. PubMed ID: 15848533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcineurin inhibitor-free immunosuppression in renal transplantation.
    Parada B; Mota A; Nunes P; Macário F; Pratas J; Bastos C; Figueiredo A
    Transplant Proc; 2005; 37(6):2759-61. PubMed ID: 16182803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function.
    Weir MR; Blahut S; Drachenburg C; Young C; Papademitriou J; Klassen DK; Cangro CB; Bartlett ST; Fink JC
    Am J Nephrol; 2004; 24(4):379-86. PubMed ID: 15237243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of immunosuppression on the incidence of early subclinical renal allograft rejection: implications for protocol biopsy policy.
    Roberts IS; Stratopoulos C; Zilvetti M; Reddy S; Friend PJ
    Transpl Int; 2009 Aug; 22(8):831-6. PubMed ID: 19386079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histological findings of early graft biopsies in old donor renal transplant patients receiving induction therapy.
    Gavela E; Pallardó LM; Sancho A; Avilla A; Beltrán S; Roselló E; Pérez ML; García F
    Transplant Proc; 2009; 41(6):2099-101. PubMed ID: 19715842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
    Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
    Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporine-sparing effect of basiliximab in renal transplant recipients with mycophenolate mofetil.
    Tojimbara T; Sato S; Koyama I; Nanmoku K; Sekijima M; Tonsyo M; Kai K; Kato Y; Urashima Y; Nakajima I; Fuchinoue S; Teraoka S
    Transplant Proc; 2005 Mar; 37(2):895-8. PubMed ID: 15848568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basiliximab and heart transplantation in Hispanics: the experience in Puerto Rico.
    Banchs HL; Carro Jiménez EJ; González V; González Cancel IF; Quintana C; Calderón R; Altieri PI; Rivera C
    Bol Asoc Med P R; 2007; 99(3):191-6. PubMed ID: 19610574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of accelerated renal allograft rejection with FK 506.
    Woodle ES; Newell KA; Haas M; Bartosh S; Josephson MA; Millis JM; Bruce DS; Piper JB; Aronson AJ; Thistlethwaite JR
    Clin Transplant; 1997 Aug; 11(4):251-4. PubMed ID: 9267710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.